trending Market Intelligence /marketintelligence/en/news-insights/trending/qspquHx0-7qNXBvMQZT5hg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Relevium to resume trading on TSX Venture Exchange

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Relevium to resume trading on TSX Venture Exchange

Relevium Technologies Inc.'s securities will resume trading as it has provided certain clarifications to the TSX Venture Exchange.

The exchange previously instructed Relevium to halt trading in its common shares in order to provide certain documents relating to its proposed acquisition of the assets of BioGanix Ltd. for $4.3 million.

Relevium will resume trading on the TSX Venture Exchange at the market opening Jan 26.

The proposed acquisition of BioGanix represents a fundamental or significant transaction and as such it is subject to the approval by the TSX Venture Exchange. The company remains engaged in the process with the exchange and is working diligently in cooperation with the vendor and external consultants to ensure the fluidity of this transaction.

BioGanix is a Houston-based, privately held nutraceutical company focused on products related to brain, heart and digestive health, as well as joint support, sold online.